Enzyme and Proton-Activated Prodrugs for a Selective Cancer Therapy

Author(s): L. F. Tietze, T. Feuerstein.

Journal Name: Current Pharmaceutical Design

Volume 9 , Issue 26 , 2003


This review is a survey of two approaches for a selective anticancer therapy that are based on a specific cleavage of specially designed non-toxic prodrugs with the liberation of a cytotoxic compound either by antibody-enzyme conjugates targeted to tumor-associated antigens or by acid-catalyzed hydrolysis of the prodrugs due to the increased concentration of hydronium ions in malignant tissue under hyperglycemic conditions. Herein, the design, synthesis and the biological testing of prodrugs are described.

Keywords: adept, antitumor agents, cancer therapy, enzymes, glycosides, monoclonal antibodies, prodrugs

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [2155 - 2175]
Pages: 21
DOI: 10.2174/1381612033454072
Price: $58

Article Metrics

PDF: 5